Pliant Therapeutics Inc. NASDAQ: PLRX

The estimated stock exchanges were observed around 29.93 USD in the share market for NasdaqGS for the PLRX. Since Pliant Therapeutics held a successful IPO earlier in June, that raised an enticing amount of $144 million. Though the much-upsized amount still feels like a pea size in front of Moderna’s $604 million IPO, questions have started to raise: Could Pliant become the next Moderna. Pliant’s (NASDAQ: PLRX at niche is the development of drugs that target fibrotic diseases, focusing over inhibition of integrin proteins suitable for releasing transforming growth bacteria beta 1 ( TGF beta 1), which further regulates Read More

ˆ Back To Top